- Disease: Acute COVID-19
- Study type: Observational Cohort Study, Treatment
- Study type descriptors: Retrospective, Single centre
- Objective: To evaluate the overall tolerability and safety of molnupiravir and nirmatrelvir/ritonavir in a real life setting by retrospectively assessing the proportions and type of adverse events detected in clinical practice
- Number of participants enrolled: 909
- Study enrolling from to
- Study includes follow-up for 30 days
Study Data
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Nirmatrelvir/Ritonavir
- Molnupiravir
External Links
Other information
The information was provided with the aid of the study investigators
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to